Table of Content


Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Gene therapy dealmaking

2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates

Chapter 3 – Leading Gene therapy deals

3.1. Introduction
3.2. Top Gene therapy deals by value

Chapter 4 – Most active Gene therapy dealmakers

4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles

Chapter 5 – Gene therapy contracts dealmaking directory

5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

Chapter 6 – Gene therapy dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Gene therapy deals by company A-Z

Appendix 2 – Gene therapy deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Gene therapy deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 – Gene therapy deals by therapy area

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 –Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene therapy partnering since 2010
Figure 2: Active Gene therapy dealmaking activity since 2010
Figure 3: Gene therapy partnering by deal type since 2010
Figure 4: Gene therapy partnering by disease type since 2010
Figure 5: Gene therapy deals with a headline value
Figure 6: Gene therapy deals with an upfront value
Figure 7: Gene therapy deals with a milestone value
Figure 8: Gene therapy deals with a royalty rate value
Figure 9: Top Gene therapy deals by value since 2010
Figure 10: Most active Gene therapy dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events